Rhami Khorfan1, Timothy J Kruser2, Julia M Coughlin3, Ankit Bharat4, Karl Y Bilimoria1, David D Odell5. 1. Surgical Outcomes and Quality Improvement Center (SOQIC), Northwestern University Feinberg School of Medicine, Chicago, Illinois. 2. Department of Radiation Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 3. Department of Surgery, Rush University Medical Center, Chicago, Illinois. 4. Division of Thoracic Surgery, Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 5. Surgical Outcomes and Quality Improvement Center (SOQIC), Northwestern University Feinberg School of Medicine, Chicago, Illinois; Division of Thoracic Surgery, Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Electronic address: dodell@nm.org.
Abstract
BACKGROUND: Stereotactic body radiation therapy (SBRT) is an accepted primary treatment option for inoperable early-stage non-small cell lung cancer (NSCLC). The role of SBRT in the treatment of operable disease remains unclear. We retrospectively evaluated patients with operable early-stage NSCLC who elected to receive primary SBRT, examined factors associated with SBRT, and compared overall survival after surgical resection and SBRT. METHODS: The National Cancer Database was queried for patients with stage I/II, N0 NSCLC from 2004 to 2016. The proportion of patients who refused recommended surgery and were treated with SBRT was calculated. A propensity score predicting the probability of refusing surgery and receiving SBRT was generated and used to match SBRT and resected patients. Long-term overall survival was compared in the matched cohort using the Kaplan-Meier method and Cox regression. RESULTS: We identified 1359 patients (0.98%) who refused recommended surgery and elected SBRT. This proportion increased annually, from 0.1% in 2004 to 1.7% in 2016. Factors associated with SBRT were older age, black race, Medicaid coverage, lower T stage, and more recent diagnosis year. Propensity matching resulted in 1315 well-balanced pairs. Surgery was associated with higher median survival (74 vs 47 months, P < .01) in the matched cohort. Survival benefit persisted after adjusting for covariates on Cox regression (hazard ratio, 1.69; P < .01). CONCLUSIONS: Median survival was significantly higher after surgery compared with SBRT in a risk-adjusted matched cohort of patients judged to be surgical candidates. Operable patients considering primary SBRT should be educated regarding this difference in survival.
BACKGROUND: Stereotactic body radiation therapy (SBRT) is an accepted primary treatment option for inoperable early-stage non-small cell lung cancer (NSCLC). The role of SBRT in the treatment of operable disease remains unclear. We retrospectively evaluated patients with operable early-stage NSCLC who elected to receive primary SBRT, examined factors associated with SBRT, and compared overall survival after surgical resection and SBRT. METHODS: The National Cancer Database was queried for patients with stage I/II, N0 NSCLC from 2004 to 2016. The proportion of patients who refused recommended surgery and were treated with SBRT was calculated. A propensity score predicting the probability of refusing surgery and receiving SBRT was generated and used to match SBRT and resected patients. Long-term overall survival was compared in the matched cohort using the Kaplan-Meier method and Cox regression. RESULTS: We identified 1359 patients (0.98%) who refused recommended surgery and elected SBRT. This proportion increased annually, from 0.1% in 2004 to 1.7% in 2016. Factors associated with SBRT were older age, black race, Medicaid coverage, lower T stage, and more recent diagnosis year. Propensity matching resulted in 1315 well-balanced pairs. Surgery was associated with higher median survival (74 vs 47 months, P < .01) in the matched cohort. Survival benefit persisted after adjusting for covariates on Cox regression (hazard ratio, 1.69; P < .01). CONCLUSIONS: Median survival was significantly higher after surgery compared with SBRT in a risk-adjusted matched cohort of patients judged to be surgical candidates. Operable patients considering primary SBRT should be educated regarding this difference in survival.
Authors: Takashi Eguchi; Sarina Bains; Ming-Ching Lee; Kay See Tan; Boris Hristov; Daniel H Buitrago; Manjit S Bains; Robert J Downey; James Huang; James M Isbell; Bernard J Park; Valerie W Rusch; David R Jones; Prasad S Adusumilli Journal: J Clin Oncol Date: 2016-10-31 Impact factor: 44.544
Authors: Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth Journal: Lancet Oncol Date: 2015-05-13 Impact factor: 41.316
Authors: Christopher D Corso; Henry S Park; Amy C Moreno; Anthony W Kim; James B Yu; Zain A Husain; Roy H Decker Journal: Am J Clin Oncol Date: 2017-08 Impact factor: 2.339
Authors: N E Verstegen; J W A Oosterhuis; D A Palma; G Rodrigues; F J Lagerwaard; A van der Elst; R Mollema; W F van Tets; A Warner; J J A Joosten; M I Amir; C J A Haasbeek; E F Smit; B J Slotman; S Senan Journal: Ann Oncol Date: 2013-02-20 Impact factor: 32.976
Authors: Varun Puri; Traves D Crabtree; Jennifer M Bell; Stephen R Broderick; Daniel Morgensztern; Graham A Colditz; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Bryan F Meyers; Aalok Patel; Clifford G Robinson Journal: J Thorac Oncol Date: 2015-12 Impact factor: 15.609
Authors: Christopher D Corso; Henry S Park; Anthony W Kim; James B Yu; Zain Husain; Roy H Decker Journal: Lung Cancer Date: 2015-05-12 Impact factor: 5.705
Authors: C Ostheimer; C Evers; F Palm; R Mikolajczyk; D Vordermark; Daniel Medenwald Journal: J Cancer Res Clin Oncol Date: 2019-09-06 Impact factor: 4.553
Authors: Henry S Park; Frank C Detterbeck; David C Madoff; Brett C Bade; Ulas Kumbasar; Vincent J Mase; Andrew X Li; Justin D Blasberg; Gavitt A Woodard; Whitney S Brandt; Roy H Decker Journal: J Thorac Dis Date: 2022-06 Impact factor: 3.005
Authors: Mara Antonoff; Leah Backhus; Daniel J Boffa; Stephen R Broderick; Lisa M Brown; Phillip Carrott; James M Clark; David Cooke; Elizabeth David; Matt Facktor; Farhood Farjah; Eric Grogan; James Isbell; David R Jones; Biniam Kidane; Anthony W Kim; Shaf Keshavjee; Seth Krantz; Natalie Lui; Linda Martin; Robert A Meguid; Shari L Meyerson; Tim Mullett; Heidi Nelson; David D Odell; Joseph D Phillips; Varun Puri; Valerie Rusch; Lawrence Shulman; Thomas K Varghese; Elliot Wakeam; Douglas E Wood Journal: Ann Thorac Surg Date: 2020-04-09 Impact factor: 4.330
Authors: Mara Antonoff; Leah Backhus; Daniel J Boffa; Stephen R Broderick; Lisa M Brown; Phillip Carrott; James M Clark; David Cooke; Elizabeth David; Matt Facktor; Farhood Farjah; Eric Grogan; James Isbell; David R Jones; Biniam Kidane; Anthony W Kim; Shaf Keshavjee; Seth Krantz; Natalie Lui; Linda Martin; Robert A Meguid; Shari L Meyerson; Tim Mullett; Heidi Nelson; David D Odell; Joseph D Phillips; Varun Puri; Valerie Rusch; Lawrence Shulman; Thomas K Varghese; Elliot Wakeam; Douglas E Wood Journal: J Thorac Cardiovasc Surg Date: 2020-04-09 Impact factor: 5.209
Authors: Michael J Littau; Richard Freeman; Wickii T Vigneswaran; Fred A Luchette; Marshall S Baker; Wissam Raad; Zaid M Abdelsattar Journal: JTCVS Open Date: 2022-01-24